Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 4/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13091047 | 0.91 | ALDH1A1 (0.47) | RENMAPTALDH1A1RECQLHPGD | |
| SCHEMBL13434188 | 0.88 | MAPT (0.46) | RENMAPTALDH1A1RECQLHPGD | |
| SCHEMBL13434196 | 0.87 | MAPT (0.45) | RENMAPTALDH1A1RECQLHPGD | |
| SCHEMBL89403 | 0.87 | REN (0.46) | RENMAPTALDH1A1RECQLHPGD | |
| SCHEMBL90227 | 0.87 | MAPT (0.44) | RENMAPTALDH1A1RECQLHPGD | |
| SCHEMBL88801 | 0.87 | MAPT (0.47) | RENMAPTALDH1A1RECQLHPGD | |
| SCHEMBL13434190 | 0.86 | REN (0.56) | RENMAPTALDH1A1RECQLHPGD | |
| SCHEMBL7606437 | 0.85 | REN (0.44) | RENSCN9AMAPTALDH1A1RECQL | |
| SCHEMBL89417 | 0.85 | REN (0.59) | RENMAPTALDH1A1RECQLHPGD | |
| SCHEMBL89089 | 0.85 | MAPT (0.43) | RENMAPTALDH1A1RECQLHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | REN 1/4885SCN9A 1385/4885MAPT 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.